Corrigendum to: Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment [Surgery. 2020 Jan;167(1):189-196. doi: 10.1016/j.surg.2019.05.092. Epub 2019 Oct 16.PMID: 31629542] (Surgery (2020) 167(1) (189–196), (S0039606019305835), (10.1016/j.surg.2019.05.092))

R. Guenter, T. Aweda, D. M. Carmona Matos, S. Jang, J. Whitt, Y. Q. Cheng, X. M. Liu, H. Chen, S. E. Lapi, R. Jaskula-Sztul

Research output: Contribution to journalComment/debate

Abstract

The authors regret not including the full funding support for this publication. The Funding/Support paragraph should be corrected as follows: Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NCATS NIH) under award number UL1TR001417 and by American Cancer Society under the award number ACS-IRG -18-162-59-IRG. The content is the sole responsibility of the authors and does not represent the official views of the National Institutes of Health. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)351
Number of pages1
JournalSurgery (United States)
Volume170
Issue number1
DOIs
StatePublished - Jul 2021

Fingerprint

Dive into the research topics of 'Corrigendum to: Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment [Surgery. 2020 Jan;167(1):189-196. doi: 10.1016/j.surg.2019.05.092. Epub 2019 Oct 16.PMID: 31629542] (Surgery (2020) 167(1) (189–196), (S0039606019305835), (10.1016/j.surg.2019.05.092))'. Together they form a unique fingerprint.

Cite this